

<https://doi.org/10.1038/s41531-025-01245-z>

Genome-wide association study of copy number variations in Parkinson's disease

Check for updates

Zied Landoulsi^{1,2}✉, Ashwin Ashok Kumar Sreelatha³, Nicole Kuznetsov^{4,5}, Claudia Schulte^{6,7}, Dheeraj Reddy Bobbili¹, Ludovica Montanucci⁸, Costin Leu^{9,10}, Lisa-Marie Niestroj¹¹, Emadeldin Hassanin¹, Cloé Domenighetti¹², Pierre-Emmanuel Sugier¹², Milena Radivojkov-Blagojevic¹³, Peter Lichtner¹³, Berta Portugal¹⁴, Connor Edsall¹⁵, Jens Krüger¹⁶, Dena G. Hernandez¹⁵, Cornelis Blauwendraat¹⁵, George D. Mellick¹⁷, Alexander Zimprich¹⁸, Walter Pirkner¹⁹, Manuela Tan²⁰, Ekaterina Rogaeva²¹, Anthony Lang^{21,22,23,24}, Sulev Koks^{25,26}, Pille Taba^{27,28}, Suzanne Lesage²⁹, Alexis Brice²⁹, Jean-Christophe Corvol^{29,30}, Marie-Christine Chartier-Harlin³¹, Eugénie Mutez³¹, Kathrin Brockmann^{6,7}, Angela B. Deutschländer^{32,33,34}, Georges M. Hadjigeorgiou^{35,36}, Efthimos Dardiotis³⁶, Leonidas Stefanis^{37,38}, Athina Maria Simitsi³⁸, Enza Maria Valente^{39,40}, Simona Petrucci^{41,42}, Letizia Straniero⁴³, Anna Zecchinelli⁴⁴, Gianni Pezzoli^{44,45}, Laura Brighina^{46,47}, Carlo Ferrarese^{46,47}, Grazia Annesi⁴⁸, Andrea Quattrone⁴⁹, Monica Gagliardi⁵⁰, Lena F. Burbulla^{7,51,52,53}, Hirotaka Matsuo⁵⁴, Akiyoshi Nakayama⁵⁴, Nobutaka Hattori⁵⁵, Kenya Nishioka⁵⁵, Sun Ju Chung⁵⁶, Yun Joong Kim⁵⁷, Lukas Pavelka², Pierre Kolber⁵⁸, Bart PC van de Warrenburg⁵⁹, Bastiaan R. Bloem⁵⁹, Andrew B. Singleton^{4,15}, Dan Vitale^{4,5}, Mathias Toft⁶⁰, Lasse Pihlstrom⁶⁰, Leonor Correia Guedes^{61,62}, Joaquim J. Ferreira^{61,63}, Soraya Bardien^{64,65}, Jonathan Carr⁶⁶, Eduardo Tolosa^{67,68}, Mario Ezquerra⁶⁹, Pau Pastor^{70,71}, Karin Wirdefeldt^{72,73}, Nancy L. Pedersen⁷³, Caroline Ran⁷⁴, Andrea C. Belin⁷⁴, Andreas Puschmann⁷⁵, Carl E. Clarke⁷⁶, Karen E. Morrison⁷⁷, Dimitri Krainc⁵¹, Matt J. Farrer⁷⁸, Dennis Lal^{8,79,80}, the Global Parkinson Genetics Program (GP2)*, Alexis Elbaz¹², Thomas Gasser^{6,7}, Rejko Krüger^{1,2,58}, Manu Sharma^{3,289}✉, Patrick May^{1,289} & on behalf of the Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease (COURAGE-PD) consortium*

We investigated the role of copy number variations (CNVs) in Parkinson's disease (PD) using genotyping data from 10,815 patients (2731 early-onset PD, EOPD) and 8901 controls from the COURAGE-PD consortium. CNVs were analyzed using a sliding window genome-wide association and burden approach. No genome-wide significant CNVs were detected in the overall cohort, but a robust deletion spanning exons 2–6 of *PRKN* was identified in EOPD cases, validated by MLPA, and replicated in the GP2 dataset (23,089 cases, 18,824 controls). CNV burden was significantly enriched in PD-related genes, primarily driven by *PRKN*, with the strongest effect observed in EOPD. *PRKN* CNV carriers showed earlier age at onset, confirmed by survival analysis. No association was observed for genome-wide or large CNV burden. Our findings reinforce the pivotal role of *PRKN* deletions in early-onset PD and highlight the need for high-resolution CNV analysis in large cohorts to uncover additional rare contributors to PD risk.

A global survey estimates that Parkinson's disease (PD) is the world's fastest-growing neurodegenerative disorder, surpassing even Alzheimer's disease¹. Concerted efforts are required to unravel the underlying complexity of a disease in which genetics and environmental factors appear to play an important role^{2,3}. To date, considerable progress has

been made in understanding the genetic basis of PD by identifying families in which the disease segregates in Mendelian fashion and by applying array-based approaches (commonly used in genome-wide association studies (GWAS)) to identify risk factors for sporadic forms of PD^{4,5}.

A full list of affiliations appears at the end of the paper. *Lists of authors and their affiliations appear at the end of the paper.

✉ e-mail: zied.landoulsi@liih.lu; manu.sharma@uni-tuebingen.de



GWAS have been successful in identifying several loci that are potentially relevant for PD^{6,7}. While this success has been remarkable, the genetic variability explained so far is between 19% and 39%⁶ indicating that the genetic variability in the form of chromosomal arrangements - duplications, deletions - commonly referred to as copy number variations (CNVs)—may be an important player in explaining the genetic variability in PD^{8–11}. Indeed, previous studies identified several CNVs in PD-related genes. For example, genomic multiplications in the *SNCA* gene were shown to cause familial¹² and sporadic¹³ forms of PD. Duplication or triplication of this gene can result in an excess of alpha-synuclein, which may then aggregate and form Lewy bodies, ultimately contributing to neurodegeneration observed in PD¹⁰. Furthermore, CNVs in *PRKN* are the most prevalent CNVs among known PD genes^{14–16}, owing to its location in one of the most mutation-susceptible regions of the human genome¹⁷. Deletions in familial PD forms were previously described in *PINK1*^{18,19} and *PARK7*^{20,21}, but are less common than in *PRKN*. Unlike *SNCA*, deletions in homozygous-driven early-onset PD (EOPD) forms have demonstrated the role of loss-of-function genes in the etiology of the disease, while the pathogenic role of single heterozygous CNVs is still controversial.

The strong implication of *PRKN*, *PINK1*, and *PARK7* in EOPD underscores the importance of CNVs in this genetically enriched subgroup, where Mendelian and structural variants more frequently contribute to disease onset. Because EOPD patients often carry bi-allelic or compound heterozygous variants that strongly influence disease progression, examining CNV burden and distribution in this group provides a powerful approach to uncover both known and novel genomic regions implicated in PD pathogenesis.

The above examples support the role of CNVs in genes that are bona-fide loci for monogenic PD. In contrast, the role and impact of CNVs on sporadic PD is still unclear. However, previous studies have suggested a potential role of CNVs in sporadic PD as well. For instance, a genome-wide CNV burden analysis in a Latin American cohort²² showed that PD patients were significantly enriched only for CNVs affecting known PD genes, but they could not identify any putative CNV in PD pathogenesis at the genome-wide level. Their failure to identify putative CNVs could be attributed to the small sample size. Similarly, another study could only validate that the CNV within the *PRKN* locus was significantly associated with PD susceptibility²³. Thus, a CNV-based GWAS in large, well-powered and well-characterized PD cohorts may reveal novel molecular pathways associated with the disease, potentially advancing efforts to understand the role of CNVs in PD pathogenesis.

The Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease (COURAGE-PD) is a worldwide collaboration consortium, aimed at understanding the roles of genetics and environment in PD^{7,24,25}. In the present study, we leveraged the genome-wide data to understand the impact of CNVs on PD in COURAGE-PD. Given the fact that there is no consensus on the best method for detecting or analyzing genome-wide significant CNVs⁹, we applied the sliding window approach²⁶ to perform CNV-GWAS, and employed genome-wide burden analyses to identify novel genome-wide significant CNV regions and to investigate their impact on the disease.

Results

COURAGE-PD cohort

The final dataset for the COURAGE-PD cohort comprised 10,815 patients with PD and 8901 controls (Supplementary Table 1), all of European descent, following genotyping QC. A total of 2731 PD patients (24.7%) were classified as having EOPD (mean AAO 43.1 ± 6.1 years; mean age at assessment 54.4 ± 9.3 years). A schematic overview of the study design and analytical workflow is presented in Fig. 1. After all quality control (QC) and filtering steps (see “Methods”), we identified 28,263 rare CNVs in 3896 PD patients and 3299 controls, with deletions being more frequent than duplications.

Overall, 36.0% of individuals carried at least one rare CNV. Further details on CNV characteristics are provided in Supplementary Table 2.

CNVs GWAS using sliding window approach

A total of 267,237 genomic segments of 200 kb size in a 10 kb sliding window approach were scanned²⁶. After multiple testing correction and fine-mapping, no genome-wide significant loci were identified (Fig. 2A).

Identification and confirmation of a *PRKN* deletion region in EOPD

To further investigate the CNV landscape in EOPD, we performed a subset analysis comparing 2731 PD patients with AAO < 50 years and controls. This revealed a robust deletion signal spanning ~590 kb at 6q26 (chr6:162,340,000–162,930,000), overlapping exons 2–6 of *PRKN*, a gene known for its involvement in autosomal recessive EOPD (Fig. 2B). The association yielded an odds ratio of 6.8 [3.52–13.14]. Experimental validation in the Tuebingen cohort using MLPA confirmed deletions in 22 out of 26 individuals (85%), including 21 both early- and late-onset PD patients and 5 controls. To further characterize these *PRKN* deletions, we examined the allelic status of carriers across all contributing cohorts. Among the 40 PD patients with *PRKN* deletions contributing to the EOPD association signal across 19 sites, 18 were screened for *PRKN* SNVs: 14 had no additional pathogenic variants, 3 carried a pathogenic SNV (R275W or C238W), and 1 carried an additional 40 bp deletion (p.Pro113Thrfs51*). Independent replication using the CNV-Finder pipeline in the GP2 dataset further supported this finding, showing a significant enrichment of this *PRKN* deletion in PD patients (OR = 1.5 [1.18–1.93], $p = 1.6 \times 10^{-5}$).

CNV burden analysis

We used logistic regression to assess rare CNV burden at the genome-wide level across predefined categories (see “Methods”). No significant differences were observed between PD patients and controls for overall CNV burden (OR = 1.04 [0.98–1.11], $p_{adj} = 0.30$), duplications (OR = 1.09 [1.01–1.17], $p_{adj} = 0.46$), or deletions (OR = 1.00 [0.93–1.08], $p_{adj} = 0.89$; Fig. 3A), suggesting that cumulative CNV burden does not contribute




Fig. 1 | Overview of the study. Schematic representation of the analysis workflow study design.

Fig. 2 | Genome-wide meta-analysis of PD and EOPD. Miami plot of the copy-number variants (CNV) genome-wide association analyses illustrating the $-\log_{10}$ transformed Bonferroni-corrected p values (DEL and DUP for deletions at the top and duplications at the bottom, mirrored respectively) for the enrichment of CNVs in cases vs. controls for each 200 kb sliding window. Results are shown for logistic regression for all the samples (A) and early-onset Parkinson's disease (EOPD) + controls (B). Adjacent chromosomes are shown in alternating light and dark colors. Genomic regions that exceeded the Bonferroni-corrected significance threshold (red line, $\alpha = 3.74 \times 10^{-6}$) were annotated with the genomic band containing the signal.





Fig. 3 | Rare CNV burden in PD and Early-onset PD patients compared to controls for different categories. A Logistic regression was used to calculate odds ratios (ORs) and Bonferroni-adjusted p values for each copy-number variants (CNV) category, and were adjusted for age, sex, and the first five principal components (PCAs). Protein-coding gene categories were defined as all coding genes except Parkinson's disease related genes (PD-related genes). * Bonferroni adjusted p values surpassing the multiple testing cut-off. Kaplan–Meier estimates of individuals (PD patients and controls in (B) and PD patients only in (C)) carrying a CNV in a PD-related gene and individuals with other or no CNVs. Probability: the probability of not having PD symptoms. Age: age at last visit for controls or age at onset for cases. Highlighting around curves indicates 95% confidence intervals.



significantly to PD risk. Similar null results were found for CNVs excluding PD-related genes (OR = 1.02 [0.96–1.09], $p_{\text{adj}} = 0.56$) and for large CNVs (>1 Mb) (OR = 0.97 [0.81–1.17], $p_{\text{adj}} = 0.89$, Fig. 3A).

In contrast, we observed a significant enrichment of CNVs in PD-related genes (OR = 1.56 [1.18–2.09], $p_{\text{adj}} = 0.0013$), particularly for exonic CNVs (OR = 1.64 [1.18–2.30], $p_{\text{adj}} = 0.013$). *PRKN* CNVs were the primary drivers of this signal (OR = 1.47 [1.10–1.98], $p_{\text{adj}} = 0.026$, Fig. 3A). Among the 229 individuals carrying CNVs in PD-related genes, 91.7% harbored *PRKN* CNVs (summarized in Supplementary Table 3 and detailed in Supplementary Data 1). Annotation with gnomAD population frequencies showed that all CNVs identified were rare (sample frequency < 0.1%) across all ancestral groups, indicating that these variants are not population-specific. These CNVs mostly involved single-copy deletions or duplications; seven were homozygous deletions found exclusively in PD patients. In total, *PRKN* CNVs were present in 135 PD patients (1.2%) and 75 controls (0.8%), with a predominance of exonic over intronic variants. Patients with *PRKN* CNVs had significantly earlier symptom onset than non-carriers (52.8 ± 11.5 vs. 58.7 ± 15.0 years, $p = 2.5 \times 10^{-5}$), and this effect was stronger among carriers of exonic variants (50.8 ± 15.5 vs. 58.0 ± 12.2 years, $p = 0.02$).

EOPD CNV burden analysis

In a subgroup analysis of 2,731 EOPD patients (AAO ≤ 50 years), we found a marked enrichment of CNVs in PD-related genes compared to controls (OR = 2.43 [1.64–3.59], $p_{\text{adj}} = 2.8 \times 10^{-5}$), with a stronger signal for exonic

CNVs (OR = 3.10 [2.00–4.81], $p_{\text{adj}} = 3.2 \times 10^{-6}$; Fig. 3A). Sixty-two EOPD patients (2.2%) carried CNVs in PD-related genes, predominantly *PRKN* CNVs ($n = 57$; 2.1%), including 48 exonic and seven intronic events. All seven homozygous *PRKN* deletions were observed in this EOPD subgroup.

We further compared EOPD to LOPD cases and found a significantly higher CNV burden in EOPD patients, particularly for PD-related and exonic CNVs, consistent with the trends seen in comparisons with controls (Supplementary Fig. 1).

Survival analysis

Kaplan–Meier analysis showed that individuals with CNVs in PD-related genes developed symptoms significantly earlier than those with CNVs in other genes or non-carriers (log-rank test $p = 7.0 \times 10^{-6}$; Fig. 3B). Cox proportional hazards models adjusted for sex and ancestry (PC1–PC5) confirmed this association (HR = 1.48 [0.1–4.8], $p = 1.2 \times 10^{-6}$). When restricted to PD patients only, those carrying CNVs in PD-related genes also had a significantly increased hazard of earlier onset compared to other patients (HR = 1.39 [0.1–4.0], $p = 4.4 \times 10^{-5}$; Fig. 3C).

Discussion

CNVs are well-established contributors to complex diseases, including epilepsy and neurodegenerative disorders^{10,22,27,28}. However, their role in sporadic PD has not been explored at a genome-wide scale. Thus, the current study aimed to extend the knowledge of potential role and impact of

CNVs on PD by leveraging well-characterized multinational PD cohorts from COURAGE-PD and the GP2 consortium. To overcome challenges in CNV detection and analysis⁹, we applied a recently developed sliding window approach²⁶, previously used to identify seizure-associated loci²⁸.

We identified and validated a genome-wide significant deletion spanning the *PRKN* gene, a well-established contributor to EOPD and in line with the known influence of AAO on the clinical heterogeneity of PD^{7,29,30}. This finding is consistent with our burden analysis, which showed that homozygous or compound heterozygous *PRKN* deletions and duplications are the most frequent cause of EOPD and familial PD^{31–33}. We did not observe significant differences in overall genome-wide CNV burden, consistent with previous studies²². However, an increased burden of CNVs overlapping PD-related genes was observed in PD patients, primarily attributed to CNVs within the *PRKN* gene. This burden was even more pronounced in EOPD patients compared to both LOPD patients and controls, supporting a subtype-specific genetic contribution. These findings align with our previous report, which showed that CNVs, especially those in *PRKN*, were enriched in PD patients and strongly associated with early-onset disease³⁴. They are further supported by prior evidence that deletions and duplications account for 43.6% of all *PRKN* variants¹⁴ and are significantly associated with an earlier PD onset.

The majority of CNVs identified in the *PRKN* gene were heterozygous, though the possibility of an undetected pathogenic variant on the other allele cannot be excluded. Heterozygous loss of *PRKN* function may increase PD risk^{35–37} and contribute to earlier AAO³⁸, although its role remains controversial. Some studies suggest that heterozygous *PRKN* CNV may promote PD through haploinsufficiency³⁶, while others, including one in individuals of European ancestry, found no association between heterozygous *PRKN* CNVs and EOPD³⁹. Consistent with these observations, we identified *PRKN* CNVs in 0.8% of controls, highlighting the importance of considering incomplete penetrance and the potential contribution of additional genetic or environmental modifiers in heterozygous carriers.

To further assess the relationship between CNVs in PD-related genes and disease onset, we performed time-to-onset analysis using survival models. Both Kaplan–Meier and Cox regression analyses confirmed that carriers of CNVs in PD-related genes had significantly earlier symptom onset, reinforcing the relevance of these variants in modifying disease trajectory.

Despite being the largest CNV-GWAS of PD to date, no additional genome-wide significant associations were identified beyond the validated deletion in *PRKN*. This underscores both the value and limitations of array-based approaches for detecting CNVs in complex diseases. The rarity of pathogenic CNVs, coupled with the resolution constraints of SNP arrays such as the NeuroChip, likely contributed to the absence of further significant findings. While our array-based approach reliably detected large deletions, such as those spanning *PRKN* exons 2–6, we could not comprehensively assess whether heterozygous *PRKN* CNV carriers harbor additional pathogenic variants on the second allele, as samples originated from multiple independent cohorts. However, given that only a subset of carriers could be assessed and few showed biallelic disruption, this limitation is unlikely to affect the overall interpretation that the CNV burden in EOPD is primarily driven by *PRKN* deletions. Future sequencing-based analyses will be essential to confirm allelic configurations and refine the contribution of *PRKN* variants to PD risk. Detection sensitivity is strongly dependent on CNV size and probe density. Arrays typically achieve high sensitivity for deletions larger than 100–200 kb but show reduced performance for smaller or single-exon events^{40–42}. Consequently, small or complex CNVs may remain undetected, leading to an underestimation of the true CNV burden in PD. Nevertheless, we have previously demonstrated the reliability of array-based CNV detection in PD genes (Infinium Global screening array), validating CNVs in an independent cohort with MLPA and achieving an overall rate of 87% and 95% specifically for *PRKN* CNVs³⁴. These findings highlight that while array-based genotyping is robust for detecting well-characterized CNVs in PD genes, it remains limited in detecting small, intergenic, or complex CNVs.

Accordingly, robust detection pipelines should be complemented by orthogonal validation methods and careful consideration of array design. To more comprehensively assess the contribution of rare CNVs to PD risk, future studies should leverage high-resolution platforms such as whole-genome sequencing and include larger, more ancestrally diverse populations.

Methods

Study cohort

The COURAGE-PD consortium includes data from 15,849 PD patients and 11,444 controls of predominantly European ancestry from 35 cohorts⁷. In our study, we used genotyping data from 22,329 individuals from 25 European ancestry cohorts originating from 15 European countries. Genotyping QC was conducted independently for each cohort, by following the standard procedure previously reported⁷. Patients with EOPD were defined as those diagnosed before the age of 50 (age at onset (AAO) $\leq$ 50 years)⁴³. To replicate our findings, we used the NeuroBooster array data⁴⁴ from the large Global Parkinson Genetics Program (GP2) cohort comprising 23,089 PD patients and 18,824 controls.

Copy number variant calling and quality control

We created a custom population B-allele frequency (BAF) and GC wave-adjusted log R ratio (LRR) intensity file using GenomeStudio (v2.0.5 Illumina) for all the samples that passed genotyping QC and employed PennCNV (v1.0.5⁴¹) to detect CNVs in our dataset. The analysis was restricted to autosomal CNVs, as calls from the sex chromosomes are often of poor quality⁴¹. We used a post-CNV calling QC pipeline including standard parameters as previously described in studies on CNV calling from SNP array data for PD²² or epilepsy^{27,28}. As a first step, adjacent CNV calls were merged into a single call if the number of overlapping markers between them was less than 20% of the total number when both segments were combined. This was followed by intensity-based QC to exclude samples with low-quality data. Samples with a LRR standard deviation of less than 0.24, an absolute value of the waviness factor of less than 0.03, and a BAF drift of less than 0.001 were retained. These thresholds correspond to the median plus 3 SDs. Furthermore, CNV calls with more than 50% overlap with known problematic genomic regions⁴¹, including centromeric, telomeric, and HLA regions, were also excluded before analysis. Next, we removed CNVs that met the following criteria: they spanned fewer than 20 SNPs, were less than 20 kilobases (kb) in length, and had an SNP density of less than 0.0001 (number of SNPs/length of CNV). For CNVs spanning at least 20 SNPs and longer than 1 Mb, SNP density was not considered. Finally, we applied a series of filters to identify rare CNVs. The first step was to assign a specific frequency count to each CNV call using PLINK v1.07⁴⁵. This was followed by applying a filter to exclude common CNVs, retaining only rare variants that overlapped with CNVs in at least 1% of all samples. In the second step, CNVs with an overlap of at least 50% with reported common CNVs (allele frequency $>$ 1%) in the Database of Genomic Variants (DGV Gold standard dataset⁴⁶) and DECIPHER population CNVs frequencies⁴⁷ were excluded. The filtered rare CNVs were annotated for gene content using refGene, including the gene name and corresponding coordinates in the hg19 assembly with ANNOVAR (v 2020-06-08). CNVs in PD-related genes were annotated for population frequencies using the gnomAD CNVs v4.1.0 (hg38). Population-specific sample frequencies (SF_all (overall frequency), SF_afr (African/African-American), SF_amr (Latino/Admixed American), SF_asj (Ashkenazi Jewish), SF_eas (East Asian), SF_fin (Finnish), SF_mid (Middle Eastern), SF_nfe (Non-Finnish European), SF_sas (South Asian) and SF_remaining (not assigned to any group)) were extracted from overlapping records. Overlaps were retained only when CNV types were concordant, and for multiple matches, the gnomAD CNV with the highest overall site count was selected. Final coordinates were harmonized between GRCh37 and GRCh38 assemblies.

Sliding windows CNV analysis and assessment of genome-wide significance

A segment-based rare CNV burden analysis was performed to identify genomic regions with a significant increase in rare CNVs in PD cases

compared to controls. This analysis was conducted separately for each type of CNV (deletion or duplication) using a sliding window approach²⁶. The sliding windows model allowed association testing of all autosomes through 267,237 sliding windows characterized by a window size of 200 kb and a step size of 10 kb, corresponding to 13,339.6 non-overlapping windows. The threshold for genome-wide significance was set to $\alpha = 3.74 \times 10^{-6}$ after Bonferroni correction for multiple testing. For each of the genomic regions, the number of overlapping CNVs was counted separately for cases and controls for deletions or duplications. We considered a minimum overlap of 10% between the CNV and the genomic window to identify the potential burden of small deletions or duplications (≥ 20 kb). To evaluate genome-wide significant windows, we applied a logistic regression, modeling disease status as the dependent variable and CNV status as the primary independent variable. The regression model was adjusted for sex, age, sub-cohort, and the first five principal components (PCs) from the population stratification procedure to account for potential confounding factors. The analysis was performed using the rCNV docker (<https://hub.docker.com/r/talkowski/rcnv>)²⁶, and custom Python (version 3.7.9) and R (version 4.3.1) scripts. To assess the impact of age at PD onset, the same analysis was subsequently stratified based on EOPD, encompassing all the control subjects and patients with EOPD.

Association fine-mapping

The observation that a considerable number of large rare CNVs involve the deletion or duplication of multiple adjacent genes, led us to hypothesize that the most associated genes were not causal, but rather gained significance due to proximity to true causal genes. This is analogous to the linkage disequilibrium effect observed in GWAS of common variants. To address this issue, Collins et al. employed a Bayesian fine-mapping algorithm to define the 95% credible set of causal elements or genes at each genome-wide significant locus for deletions and duplications²⁶. This method prioritizes the most probable causal genes based on their association statistics. The Bayesian algorithm was employed to calculate the approximate Bayes factor (ABF) for each window, as previously described by Wakefield⁴⁸. The ABF offers an alternative to the *P* values for assessing the significance of association by providing a summary measure that ranks these associations. Bayesian model averaging was used to estimate the null variance of true causal loci across taking into account prior information regarding the mean of all significant windows and the most significant window per block. The minimal set of windows that constitutes the 95% credible set for each block was defined by ranking the windows in descending order according to their ABF.

CNV replication using CNV-Finder

To replicate CNVs identified in our discovery dataset, we applied CNV-Finder (<https://github.com/GP2code/CNV-Finder>)⁴⁹, a deep learning-based pipeline designed for CNV detection from Illumina genotyping arrays. CNV-Finder utilizes a Long Short-Term Memory neural network trained on expert-annotated LRR and BAF signals to detect deletions and duplications within predefined genomic regions. The pipeline allowed for filtering based on prediction confidence, LRR signal range, and variant count. Predictions were reviewed visually and used to prioritize samples for downstream validation.

Genome-wide burden and survival analysis

The burden of rare CNVs associated with PD was calculated using distinct categories to determine their relative impact on PD risk, as previously reported²². These categories included: (1) carrier status of genome-wide CNV burden, including CNVs in non-genic regions, for all CNVs, not distinguishing between deletions and duplications (2) carrier status of any exonic or intronic CNVs intersecting with ‘any gene’ except those associated with PD, (3) carrier status of CNVs intersecting with exonic or intronic regions of the six major ‘PD-related genes’ according to MDS gene classification (<https://www.mdsgene.org>): *LRRK2*, *SNCA*, *VPS35* for dominant forms of classical parkinsonism and *PRKN*, *PARK7*, and *PINK1* for recessive

forms of early-onset parkinsonism, (4) carrier status of CNVs intersecting only with exonic regions of the ‘PD-related genes’, (5) carrier status of CNVs in *PRKN* only and (6) carrier status of large CNVs (≥ 1 Mb in length). To compare the CNV burden between PD patients and controls, we used the *glm* function in R (v4.3.1) to fit a logistic regression model. This allowed the calculation of the OR with a 95% confidence interval and *p* values. We used sex, age at assessment, and the first five PCs from the population stratification as covariates for the regression model. Cox proportional hazards regression analyses and Kaplan–Meier curves were generated using the *survival* R package⁵⁰ with age defined as age at last visit for controls and AAO for cases. Controls were included as censored observations given that it was only known that they did not develop PD up to their last visit. Hazard ratios and 95% confidence intervals of PD were estimated by Cox proportional hazards models. Sex and the first five PCs were included as covariates. All the *P* values underwent adjustment using the Bonferroni method to correct for multiple testing.

Ethics approval

All participants signed a written informed consent according to the Declaration of Helsinki. The ethical approval was obtained by the local institutional review board of the respective study sites. All the study participants provided signed informed consent.

Data availability

Individual-level CNVs and genotyping data are available on request from the COURAGE-PD consortium. Relevant scripts used in the present work are available on GitHub (https://gitlab.lcsb.uni.lu/genomeanalysis/cnv_gwas_courage-pd). For the sliding window association method, we used the code available under the Talkowski Laboratory (Massachusetts General Hospital & The Broad Institute) repository in Zenodo (<https://github.com/talkowski-lab/rCNV2/tree/v1.0>, with <https://zenodo.org/records/6647918>).

Received: 24 August 2025; Accepted: 16 December 2025;

Published online: 20 April 2026

References

- Steinmetz, J. D. et al. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet Neurol.* **23**, 344–381 (2024).
- Lim, S.-Y. & Klein, C. Parkinson’s disease is predominantly a genetic disease. *J. Parkinson’s Dis.* **14**, 467–482 (2024).
- Dorsey, E. R. & Bloem, B. R. Parkinson’s disease is predominantly an environmental disease. *J. Parkinson’s Dis.* **14**, 451–465 (2024).
- Kasten, M. et al. Genotype-phenotype relations for the Parkinson’s disease genes *Parkin*, *PINK1*, *DJ1*: MDSGene systematic review. *Mov. Disord.* **33**, 730–741 (2018).
- Blauwendraat, C., Nalls, M. A. & Singleton, A. B. The genetic architecture of Parkinson’s disease. *Lancet Neurol.* **19**, 170–178 (2020).
- Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. *Lancet Neurol.* **18**, 1091–1102 (2019).
- Grover, S. et al. Genome-wide association and meta-analysis of age at onset in Parkinson disease: evidence from the COURAGE-PD Consortium. *Neurology* **99**, e698–e710 (2022).
- Toft, M. & Ross, O. A. Copy number variation in Parkinson’s disease. *Genome Med.* **2**, 62 (2010).
- La Cognata, V., D’Agata, V., Cavalcanti, F. & Cavallaro, S. Genetics of Parkinson’s disease: the role of copy number variations. in *Challenges in Parkinson’s Disease* (eds Dorszewska, J. & Kozubski, W.). <https://doi.org/10.5772/62881> (InTech, 2016).
- La Cognata, V., Morello, G., D’Agata, V. & Cavallaro, S. Copy number variability in Parkinson’s disease: assembling the puzzle through a systems biology approach. *Hum. Genet.* **136**, 13–37 (2017).

11. Miano-Burkhardt, A., Alvarez Jerez, P., Daida, K., Bandres Ciga, S. & Billingsley, K. J. The role of structural variants in the genetic architecture of Parkinson's disease. *Int. J. Mol. Sci.* **25**, 4801 (2024).
12. Singleton, A. B. et al. α -synuclein locus triplication causes Parkinson's disease. *Science* **302**, 841–841 (2003).
13. Ahn, T.-B. et al. α -Synuclein gene duplication is present in sporadic Parkinson disease. *Neurology* **70**, 43–49 (2008).
14. Menon, P. J. et al. Genotype–phenotype correlation in PRKN-associated Parkinson's disease. *npj Parkinsons Dis.* **10**, 72 (2024).
15. Pankratz, N. et al. *Parkin* dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. *Neurology* **73**, 279–286 (2009).
16. Kay, D. M. et al. A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2. *Neurology* **75**, 1189–1194 (2010).
17. Ambroziak, W. et al. Genomic instability in the PARK2 locus is associated with Parkinson's disease. *J. Appl. Genet.* **56**, 451–461 (2015).
18. Cazeneuve, C. et al. A new complex homozygous large rearrangement of the PINK1 gene in a Sudanese family with early onset Parkinson's disease. *Neurogenetics* **10**, 265–270 (2009).
19. Darvish, H. et al. Detection of copy number changes in genes associated with Parkinson's disease in Iranian patients. *Neurosci. Lett.* **551**, 75–78 (2013).
20. Bonifati, V. et al. Mutations in the *DJ-1* gene associated with autosomal recessive early-onset Parkinsonism. *Science* **299**, 256–259 (2003).
21. Macedo, M. G. et al. Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson's disease. *Mov. Disord.* **24**, 196–203 (2009).
22. Sarihan, E. I. et al. Genome-wide analysis of copy number variation in Latin American Parkinson's disease patients. *Mov. Disord.* **36**, 434–441 (2021).
23. Pankratz, N. et al. Copy number variation in familial Parkinson disease. *PLoS ONE* **6**, e20988 (2011).
24. Grover, S. et al. Replication of a novel Parkinson's locus in a European ancestry population. *Mov. Disord.* **36**, 1689–1695 (2021).
25. Domenighetti, C. et al. Dairy intake and Parkinson's disease: a Mendelian randomization study. *Mov. Disord.* **37**, 857–864 (2022).
26. Collins, R. L. et al. A cross-disorder dosage sensitivity map of the human genome. *Cell* **185**, 3041–3055.e25 (2022).
27. Niestroj, L.-M. et al. Epilepsy subtype-specific copy number burden observed in a genome-wide study of 17,458 subjects. *Brain* **143**, 2106–2118 (2020).
28. Montanucci, L. et al. Genome-wide identification and phenotypic characterization of seizure-associated copy number variations in 741,075 individuals. *Nat. Commun.* **14**, 4392 (2023).
29. Blauwendraat, C. et al. Parkinson's disease age at onset genome-wide association study: defining heritability, genetic loci, and α -synuclein mechanisms. *Mov. Disord.* **34**, 866–875 (2019).
30. Pavelka, L. et al. Age at onset as stratifier in idiopathic Parkinson's disease—effect of ageing and polygenic risk score on clinical phenotypes. *npj Parkinsons Dis.* **8**, 102 (2022).
31. Domingo, A. & Klein, C. Genetics of Parkinson disease. in *Handbook of Clinical Neurology* Vol. 147, 211–227 (Elsevier, 2018).
32. Ahmad, A., Nkosi, D. & Iqbal, M. A. PARK2 microdeletion or duplications have been implicated in different neurological disorders including early onset Parkinson disease. *Genes* **14**, 600 (2023).
33. Elfferich, P. et al. Breakpoint mapping of 13 large parkin deletions/duplications reveals an exon 4 deletion and an exon 7 duplication as founder mutations. *Neurogenetics* **12**, 263–271 (2011).
34. Landoulsi, Z. et al. Large-scale copy number variant analysis in genes linked to Parkinson's disease. *npj Parkinsons Dis.* **11**, 225 (2025).
35. Castelo Rueda, M. P. et al. Frequency of heterozygous Parkin (PRKN) variants and penetrance of Parkinson's disease risk markers in the population-based CHRIS cohort. *Front. Neurol.* **12**, 706145 (2021).
36. Klein, C., Lohmann-Hedrich, K., Rogaeva, E., Schlossmacher, M. G. & Lang, A. E. Deciphering the role of heterozygous mutations in genes associated with Parkinsonism. *Lancet Neurol.* **6**, 652–662 (2007).
37. Lubbe, S. J. et al. Assessing the relationship between monoallelic *PRKN* mutations and Parkinson's risk. *Hum. Mol. Genet.* **30**, 78–86 (2021).
38. Sun, M. et al. Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. *Arch. Neurol.* **63**, 826 (2006).
39. Yu, E. et al. Analysis of heterozygous *PRKN* variants and copy-number variations in Parkinson's disease. *Mov. Disord.* **36**, 178–187 (2021).
40. Pinto, D. et al. Comprehensive assessment of array-based platforms and calling algorithms for detection of copy number variants. *Nat. Biotechnol.* **29**, 512–520 (2011).
41. Wang, K. et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. *Genome Res.* **17**, 1665–1674 (2007).
42. Macé, A. et al. New quality measure for SNP array based CNV detection. *Bioinformatics* **32**, 3298–3305 (2016).
43. Mehanna, R. et al. Age cutoff for early-onset Parkinson's disease: recommendations from the International Parkinson and Movement Disorder Society task force on early onset Parkinson's disease. *Mov. Disord. Clin. Pract.* **9**, 869–878 (2022).
44. Bandres-Ciga, S. et al. Neurobooster array: a genome-wide genotyping platform to study neurological disorders across diverse populations. *Mov. Disord.* **39**, 2039–2048 (2024).
45. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.* **81**, 559–575 (2007).
46. MacDonald, J. R., Ziman, R., Yuen, R. K. C., Feuk, L. & Scherer, S. W. The Database of Genomic Variants: a curated collection of structural variation in the human genome. *Nucleic Acids Res.* **42**, D986–D992 (2014).
47. Bragin, E. et al. DECIPHER: database for the interpretation of phenotype-linked plausibly pathogenic sequence and copy-number variation. *Nucleic Acids Res.* **42**, D993–D1000 (2014).
48. Wakefield, J. Bayes factors for genome-wide association studies: comparison with *P*-values. *Genet. Epidemiol.* **33**, 79–86 (2009).
49. Kuznetsov, N. et al. CNV-Finder: streamlining copy number variation discovery. Preprint at <https://doi.org/10.1101/2024.11.22.624040> (2024).
50. Therneau, T. M. Survival: survival analysis. 3.7–0 <https://doi.org/10.32614/CRAN.package.survival> (2001).

Acknowledgements

This study used data from the Courage-PD consortium, conducted under a partnership agreement among 35 studies. The Courage-PD consortium is supported by the EU Joint Program for Neurodegenerative Disease research (JPND <https://neurodegenerationresearch.eu>). This project was supported by the Global Parkinson's Genetics Program (GP2; <https://gp2.org>). GP2 is funded by the Aligning Science Across Parkinson's (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson's Research (MJFF). P.M. was funded by the Fonds National de Recherche (FNR), Luxembourg, as part of the National Centre of Excellence in Research on Parkinson's Disease (NCER-PD, FNR11264123). Z.L. and P.M. were supported by the DFG Research Unit FOR2715 (INTER/DFG/17/11583046), FOR2488 (INTER/DFG/19/14429377) and the National Centre for Excellence in Research on Parkinson's disease (NCER-PD). A.B.S., D.G.H., and C.E. are funded by the Intramural Research Program of the National Institute on Aging, National Institutes of Health, Department of Health and Human Services, project ZO1 AG000949. E.R. is funded by the Canadian Consortium on Neurodegeneration in Aging. S.K. is funded by MSWA. P.T. is the recipient of an Estonian Research Council Grant PRG957. E.M.V. is funded by the Italian Ministry of Health (Ricerca Corrente 2021). S.B. and J.C. are

supported by grants from the National Research Foundation of South Africa (grant number: 106052); the South African Medical Research Council (Self-Initiated Research Grant); and Stellenbosch University, South Africa; they also acknowledge the support of the NRF-DST Centre of Excellence for Biomedical Tuberculosis Research; South African Medical Research Council Centre for Tuberculosis Research; and Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town. P. Pastor have received funding from the Spanish Ministry of Science and Innovation (SAF2013-47939-R). K.W. and N.L.P. are funded by the Swedish Research Council, grant numbers K2002-27X-14056-02B, 521-2010-2479, 521-2013-2488, and 2017-02175. N.L.P. is funded by the National Institutes of Health, grant numbers ES10758 and AG 08724. C.R. is funded by the Märta Lundkvist Foundation, Swedish Brain Foundation, and Karolinska Institutet Research Fund. A.C.B. is funded by the Swedish Brain Foundation, Swedish Research Council, and Karolinska Institutet Research Funds. M.T. is funded by the Parkinson's UK. M.S. was supported by grants from the German Research Council (DFG/SH 599/6-1), MSA Coalition, and The Michael J. Fox Foundation (USA Genetic Diversity in PD Program: GAP-India Grant ID: 17473). A.E. reports grants from Agence nationale de recherche (ANR), The Michael J. Fox Foundation, Plan Eco-phyto (French Ministry of Agriculture), and France Parkinson outside the submitted work. PG GEN sample collection was funded by the MRC and UK Medical Research Council (C.E.C. and K.E.M.). The sponsors had no role in the study design, data collection, data analysis, data interpretation, writing of the report, or decision to submit the paper for publication.

Author contributions

Z.L., P.M., M.S., R.K. contributed to the conception and design of the study. Z.L., A.A.K.S., N.K., C.S., D.R.B., L.M., C.L., L.M.N., E.H., C.D., L.Pavelka, P.-E.S., M.R., P.L., B.P., C.E., J.K., D.G.H., C.B., G.D.M., A. Zimprich, W.P., M. Tan., E.R., A.L., S.K., P.T., S.L., A.B., J.-C.C., M.-C.C.-H., E.M., K.B., A.B.D., G.M.H., E.D., L. Stefanis, A.M.S., D.V., E.M.V., S.P., L. Straniero, A. Zecchinelli, G.P., L.B., C.F., G.A., A.Q., M.G., L.F.B., H.M., A.N., N.H., K.N., S.J.C., Y.J.K., P.K., B.P.C.v.d.W., B.R.B., A.B.S., M. Toft, L. Pihlstrom, L.C.G., J.J.F., S.B., J.C., E.T., M.E., P.P., K.W., N.L.P., C.R., A.C.B., A.P., C.E.C., K.E.M., D.K., M.J.F., A.E., T.G., D.L contributed to the acquisition and analysis of data. Z.L., P.M., M.S., R.K. contributed to drafting the text or preparing the figures. All the authors contributed to revise the manuscript and approved the submitted version.

Competing interests

K.B reports consulting for F. Hoffmann-La Roche Ltd. and Vanqua Bio. J.C.C. served on advisory boards of Biogen, Denali, and UCB. L.S. has served on advisory boards and received honoraria from AbbVie, Biogen, and

Sanofi. R.K. reports nonfinancial support from AbbVie and Zambon during the conduct of the study. B.R.B. reports grants from UCB and AbbVie during the conduct of the study. J.J.F reports grants and personal fees from AbbVie, Biogen, Novartis, Bial, Medtronic, Teva. E.T. reports consultancy honoraria from Teva, Bial, Biogen, Roche, Boehringer Ingelheim, and Prevail Therapeutics. N.H reports personal fees and other support from multiple pharmaceutical companies. T.G. holds a patent (EP1802749 A2) related to the LRRK2 gene for neurodegenerative disease diagnosis and therapy. M.S. serves on the scientific advisory board of Vanqua Bio. All other authors: nothing to report.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41531-025-01245-z>.

Correspondence and requests for materials should be addressed to Zied Landoulsi or Manu Sharma.

Reprints and permissions information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

© The Author(s) 2026

¹Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg. ²Transversal Translational Medicine, Luxembourg Institute of Health, Strassen, Luxembourg. ³Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany. ⁴Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging, National Institutes of Health, Bethesda, USA. ⁵DataTecnica LLC, Washington, DC 20037, USA. ⁶Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany. ⁷German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany. ⁸Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA. ⁹Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, London, UK. ¹⁰Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. ¹¹Cologne Center for Genomics (CCG), Medical Faculty of the University of Cologne, Cologne, Germany. ¹²Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, CESP, 94805 Villejuif, France. ¹³Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany. ¹⁴Department of Precision Health, Luxembourg Institute of Health, Strassen, Luxembourg. ¹⁵Molecular Genetics Section, Laboratory of Neurogenetics, NIA, NIH, Bethesda 20892, USA. ¹⁶Group of Applied Bioinformatics, University of Tübingen, Tübingen, Germany. ¹⁷Griffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan, Queensland, Australia. ¹⁸Department of Neurology, Medical University of Vienna, Vienna, Austria. ¹⁹Department of Neurology, Klinik Ottakring, Vienna, Austria. ²⁰Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK. ²¹Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada. ²²Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada. ²³Division of Neurology, University of Toronto, Toronto, Ontario, Canada. ²⁴Krembil Brain Institute, Toronto, Ontario, Canada. ²⁵Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, Australia. ²⁶Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, Australia. ²⁷Department of Neurology and Neurosurgery, University of Tartu, Tartu, Estonia. ²⁸Neurology Clinic, Tartu University Hospital, Tartu, Estonia. ²⁹Sorbonne Université, Paris Brain Institute – ICM, Inserm, CNRS, Paris, France. ³⁰Assistance Publique Hôpitaux de Paris, Department of Neurology, CIC Neurosciences, Pitié-Salpêtrière Hospital, Paris, France.

³¹Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Lille Neurosciences & Cognition, F-59000 Lille, France. ³²Department of Neurology, Ludwig Maximilians University of Munich, Munich, Germany. ³³Department of Neurology, Max Planck Institute of Psychiatry, Munich, Germany. ³⁴Department of Neurology and Department of Clinical Genomics, Mayo Clinic Florida, Jacksonville, FL, USA. ³⁵Department of Neurology, Medical School, University of Cyprus, Nicosia, Cyprus. ³⁶Department of Neurology, Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece. ³⁷Center of Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece. ³⁸st1 Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. ³⁹Department of Molecular Medicine, University of Pavia, Pavia, Italy. ⁴⁰Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation, Pavia, Italy. ⁴¹UOC Medical Genetics and Advanced Cell Diagnostics, S. Andrea University Hospital, Rome, Italy. ⁴²Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy. ⁴³Department of Biomedical Sciences - Humanitas University, Milan, Italy. ⁴⁴Parkinson Institute, Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia. ⁴⁵Fondazione Grigioni per il Morbo di Parkinson, Milan, Italy. ⁴⁶Department of Neurology, San Gerardo Hospital, Milan, Italy. ⁴⁷Center for Neuroscience, University of Milano Bicocca, Monza, Italy. ⁴⁸Institute for Biomedical Research and Innovation, National Research Council, Cosenza, Italy. ⁴⁹Institute of Neurology, Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy. ⁵⁰Department of Medical and Surgical Sciences, Neuroscience Research Center, Magna Graecia University, Catanzaro, Italy. ⁵¹Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA. ⁵²Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University, Munich, Germany. ⁵³Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. ⁵⁴Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Saitama 359-8513, Japan. ⁵⁵Department of Neurology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan. ⁵⁶Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. ⁵⁷Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea. ⁵⁸Centre Hospitalier du Luxembourg, Parkinson Research Clinic, Luxembourg, Luxembourg. ⁵⁹Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands. ⁶⁰Department of Neurology, Oslo University Hospital, Oslo, Norway. ⁶¹Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. ⁶²Department of Neurosciences and Mental Health, Neurology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (CHULN), Lisbon, Portugal. ⁶³Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. ⁶⁴Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa. ⁶⁵South African Medical Research Council / Stellenbosch University Genomics of Brain Disorders Research Unit, Stellenbosch University, Cape Town, South Africa. ⁶⁶Division of Neurology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa. ⁶⁷Parkinson's disease & Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain. ⁶⁸Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII), Barcelona, Spain. ⁶⁹Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, ES-08036 Barcelona, Catalonia, Spain. ⁷⁰Fundació per la Recerca Biomèdica i Social Mútua Terrassa, Terrassa, Barcelona, Spain. ⁷¹Movement Disorders Unit, Department of Neurology, Hospital Universitari Mútua de Terrassa, Terrassa, Barcelona, Spain. ⁷²Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. ⁷³Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. ⁷⁴Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden. ⁷⁵Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Gatingevägen 4, 221 85 Lund, Sweden. ⁷⁶University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom. ⁷⁷Faculty of Medicine, Health and Life Sciences, Queens University, Belfast, United Kingdom. ⁷⁸Department of Neurology, McKnight Brain Institute, University of Florida, Gainesville, FL, USA. ⁷⁹Epilepsy Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA. ⁸⁰Stanley Center for Psychiatric Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. ²⁸⁹These authors contributed equally: Manu Sharma, Patrick May.

✉ e-mail: zied.landoulsi@lih.lu; manu.sharma@uni-tuebingen.de

the Global Parkinson Genetics Program (GP2)

Yasser Mecheri⁸¹, Emilia M. Gatto⁸², Marcelo Kauffman⁸³, Federico Capparelli⁸⁴, Samson Khachatryan⁸⁵, Zaruhi Tavadyan⁸⁵, Mariam Isayan⁸⁵, Claire E. Shepherd⁸⁶, Kishore Kumar⁸⁷, Melina Ellis⁸⁸, Miguel E. Rentería⁸⁹, Sulev Koks^{25,26}, Simon Rowe⁸⁶, Dennis Yeow⁸⁶, Carolyn Sue⁸⁶, Victor Flores Ocampo⁹⁰, Laura Rudaks⁹¹, Alexander Zimprich¹⁸, Kanan Jafarov⁹², David Crosiers⁹³, Artur F. Schumacher-Schuh⁹⁴, Carlos Rieder⁹⁵, Paula Saffie Awad⁹⁶, Vitor Tumas⁹⁷, Sarah Camargos⁹⁸, Lucas Faria Costa⁹⁸, Oury Monchi⁹⁹, Edward Fon¹⁰⁰, Robert Thibault¹⁰¹, Ziv Gan-Or¹⁰⁰, Anthony Lang^{21,22,23,24}, Konstantin Senkevich¹⁰⁰, Marcelo Miranda¹⁰², Maria Leonor Bustamante¹⁰³, Pedro Chana-Cuevas¹⁰⁴, Patricio Alejandro Olguín Aguilera¹⁰⁵, Elias Fernandez-Toledo¹⁰⁶, Benjamin Pizarro Galleguillos¹⁰⁷, Beisha Tang¹⁰⁸, Huifang Shang¹⁰⁹, Jifeng Guo¹¹⁰, Piu Chan¹¹¹, Wei Luo¹¹², Zhenhua Liu¹¹³, Gonzalo Arboleda¹¹⁴, Jorge Orozco¹¹⁵, Marlene Jimenez del Rio¹¹⁶, Alvaro Hernandez¹¹⁷, Per Borghammer¹¹⁸, Mohamed Salama¹¹⁹, Walaa A. Kamel¹²⁰, Yared Z. Zewde¹²¹, Alexis Brice²⁹, Jean-Christophe Corvol^{29,30}, Mari Vidailhet¹²², Mariam Kekenadze¹²³, Irine Khatiaashvili¹²⁴, Ana Westerberger¹²⁵, Anastasia Illarionova¹²⁶, Brit Mollenhauer¹²⁷, Christine Klein¹²⁵, Eva-Juliane Vollstedt¹²⁵, Franziska Hopfner¹²⁸, Günter Höglinger¹²⁸, Harutyun Madoev¹²⁵, Joanne Trinh¹²⁵, Katja Lohmann¹²⁵, Lara M. Lange¹²⁹, Manu Sharma^{3,289}✉, Sergiu Groppa¹³⁰, Thomas Gasser^{6,7}, Zih-Hua Fang¹³¹, Karl Heilbron¹³², Theresa Luth¹²⁵, Wenhua Sun¹³³, Inke König¹²⁵, Daniela Berg¹³⁴, Bernhard Haslinger¹³⁵, Teresa Kleinz¹²⁵, Norbert Brüggemann¹²⁵, Albert Akpalu¹³⁶, Georgia Xiomerisiou¹³⁷, Georges M. Hadjigeorgiou^{35,36}, Ioannis Dagklis¹³⁸, Ioannis Tamasas¹³⁹, Leonidas Stefanis^{37,38}, Maria Stamelou¹⁴⁰, Efthimos Dardiotis³⁶, Alex Medina¹⁴¹, Germaine Hiu-Fai Chan¹⁴², Nancy Ip¹⁴³, Nelson Yuk-Fai Cheung¹⁴², Phillip Chan¹⁴³, Xiaopu Zhou¹⁴³, Asha Kishore¹⁴⁴, KP Divya¹⁴⁵, Pramod Pal¹⁴⁶, Prashanth Lingappa Kukkle¹⁴⁷, Roopa Rajan¹⁴⁸, Rupam Borgohain¹⁴⁹, Mehri Salari¹⁵⁰, Tamara Shiner¹⁵¹, Avner Thaler¹⁵¹, Andrea Quattrone⁴⁹, Enza Maria Valente^{39,40}, Grazia Annesi⁴⁸, Lucilla Parnetti¹⁵², Micol Avenali¹⁵³, Monica Gagliardi⁵⁰, Tommaso Schirinzi¹⁵⁴, Caterina Galandra¹⁵⁵, Anna De Rosa¹⁵⁶, Manabu Funayama⁵⁵, Nobutaka Hattori⁵⁵, Tomotaka Shiraishi¹⁵⁷, Altnay Karimova¹⁵⁸, Gulnaz Kaishibayeva¹⁵⁸, Aigerim Utegenova¹⁵⁹, Aigul Yemagambetova¹⁵⁹, Vadim Akhmetzhanov¹⁶⁰,

Seitzhan Aidarov¹⁶¹, Tautanova Raushan¹⁶², Bagyzhan Syzdykova¹⁶³, Dinara Alzhanova¹⁶², Zhanybek Myrzayev¹⁶⁴, Saltanat Abdraimova¹⁶⁵, Cholpon Shambetova¹⁶⁶, Rejko Krüger^{1,2,58}, Patrick May^{1,289}, Ai Huey Tan¹⁶⁷, Azlina Ahmad-Annuar¹⁶⁷, Mohamed Ibrahim Norlinah¹⁶⁸, Nor Azian Abdul Murad¹⁶⁹, Shahrul Azmin¹⁷⁰, Shen-Yang Lim¹⁶⁷, Wael Mohamed¹⁷¹, Yi Wen Tay¹⁶⁷, Azalea Tenerife Pajo¹⁶⁷, Daniel Martinez-Ramirez¹⁷², Mayela Rodriguez-Violante¹⁷³, Paula Reyes-Pérez¹⁷⁴, Alejandra Medina Rivera¹⁷⁴, Nancy Monroy Jaramillo¹⁷⁵, Bayasgalan Tserensodnom¹⁷⁶, Rajeev Ojha¹⁷⁷, Wilma Van De Berg¹⁷⁸, Bastiaan R. Bloem⁵⁹, Bart PC Van de Warrenburg⁵⁹, Lisette Charbonnier¹⁷⁹, Tim J. Anderson¹⁸⁰, Toni L. Pitcher¹⁸⁰, Arinola Sanyaolu¹⁸¹, Njideka Okubadejo¹⁸¹, Oluwadamilola Ojo¹⁸², Simon Izuchukwu Ozomma¹⁸³, Kolawole Wahab¹⁸⁴, Lasse Pihlstrom⁶⁰, Manuela Tan²⁰, Ingeborg Haugesag Lie¹⁸⁵, Jodi Maple-Grødem¹⁸⁶, Shoaib Ur-Rehman¹⁸⁷, Mario Cornejo-Olivas¹⁸⁸, Maria Leila Doquenía¹⁸⁹, Raymond Rosales¹⁸⁹, Angel Vinuela¹⁹⁰, Elena Iakovenko¹⁹¹, Anna Gareeva¹⁹², Gulnara Akhmadeeva¹⁹³, Irina Gilyazova¹⁹⁴, Bashayer Al Mubarak¹⁹⁵, Muhammad Umair¹⁹⁶, Eng-King Tan¹⁹⁷, Jia Nee Foo¹⁹⁸, Elaine Chew¹⁹⁸, Vesna van Midden¹⁹⁹, Ferzana Amod²⁰⁰, Jonathan Carr⁶⁶, Soraya Bardien^{64,65}, Nikita Pillay²⁰¹, Kathryn Step²⁰², Beomseok Jeon²⁰³, Yun Joong Kim²⁰⁴, Jung Hwan Shin²⁰⁵, Joowon Jang²⁰⁵, Esther Cubo²⁰⁶, Ignacio Alvarez²⁰⁷, Janet Hoenicka²⁰⁸, Katrin Beyer²⁰⁹, Maria Teresa Perinán²¹⁰, Pau Pastor^{70,71}, Ruben Fernandez-Santiago²¹¹, Pilar Gómez Garre²¹⁰, Pablo Mir²¹⁰, Sarah El-Sadig²¹², Kajsa Brolin²¹³, Per Svenningsson²¹⁴, Maria Swanberg²¹³, Christiane Zweier²¹⁵, Gerd Tinkhauser²¹⁶, Paul Krack²¹⁵, Chin-Hsien Lin²¹⁷, Hsiu-Chuan Wu²¹⁸, Pin-Jui Kung²¹⁹, Ruey-Meei Wu²¹⁷, Yihru Wu²¹⁸, Ganieva Manizha²²⁰, Rim Amouri²²¹, Samia Ben Sassi²²¹, A.Nazlı Başak²²², Gencer Genc²²³, Özgür Öztıp Çakmak²²², Sibel Ertan²²², Alastair Noyce²²⁴, Alejandro Martínez-Carrasco²²⁵, Anette Schrag²²⁵, Anthony Schapira²²⁵, Camille Carroll²²⁶, Donald Grosset²²⁷, Eleanor J. Stafford²²⁵, Henry Houlden²²⁵, Huw R. Morris²²⁵, John Hardy²²⁵, Kin Ying Mok²²⁵, Mie Rizig²²⁵, Nicholas Wood²²⁵, Nigel Williams²²⁸, Olaitan Okunoye²²⁵, Rauan Kaiyrzhanov²²⁵, Rimona Weil²²⁵, Seth Love²²⁹, Simona Jasaityte²²⁵, Sumit Dey²²⁴, Vida Obese²²⁵, Spencer Finch²²⁴, Valentina Escott-Price²²⁸, Hamin Lee²³⁰, Roger Barker²³¹, Mina Ryten²²⁵, Michele Hu²³², Laura Parkkinen²³², Kailash Bhatia²²⁵, Richard Walker²³³, Steve Gentleman²³⁴, Thomas Warner²²⁵, David Burn²³⁵, Christian Lambert²³⁴, Caroline Williams-Gray²³¹, Chris Morris²³⁵, Deborah Attuah²³⁶, Raquel Real²²⁵, Yen Tai²³⁴, Alberto Espay²³⁷, Alyssa O'Grady²³⁸, Andrew B. Singleton^{4,15}, Andrew K. Sobering²³⁹, Bernadette Siddiqi²³⁸, Bradford Casey²³⁸, Brian Fiske²³⁸, Cabell Jonas²⁴⁰, Carlos Cruchaga²⁴¹, Caroline B. Pantazis²⁴², Charisse Comart²³⁸, Claire Wegel²⁴³, Cornelis Blauwendraat²⁴², Dan Vitale²⁴², Deborah Hall²⁴⁴, Dena Hernandez¹⁵, Ejaz Shiamim²⁴⁵, Ekemini Riley²⁴⁶, Faraz Faghri²⁴², Geidy E. Serrano²⁴⁷, Hampton Leonard²⁴⁸, Hirotaka Iwaki²⁴⁹, Honglei Chen²⁵⁰, Ignacio F. Mata²⁵¹, Ignacio Juan Keller Sarmiento²⁵², Jared Williamson²⁴⁵, Jonggeol Jeff Kim²⁴², Joseph Jankovic²⁵³, Joshua Shulman²⁵⁴, Justin C. Solle²³⁸, Kaileigh Murphy²³⁸, Kamalini Ghosh Galvelis²⁵⁵, Karen Nuytemans²⁵⁶, Karl Kiebert²⁵⁷, Kate Andersh²⁴⁸, Katerina Markopoulou²⁵⁸, Kenneth Marek²⁵⁹, Kristin S. Levine²⁴⁹, Lana M. Chahine²⁶⁰, Laura Ibanez²⁶¹, Laurel Screven²⁴⁸, Lauren Ruffrage²⁶², Lisa Shulman²⁶³, Luca Marsili²³⁷, Maggie Kuhl²³⁸, Marissa Dean²⁶², Mary B. Makarious²⁴², Matt J. Farrer⁷⁸, Mathew Koretsky²⁴², Megan J. Puckelwartz²⁶⁴, Miguel Inca-Martinez²⁵¹, Mike A. Nalls²⁴², Naomi Louie²³⁸, Niccolò Emanuele Mencacci²⁵², Roger Albin²⁶⁵, Roy Alcalay²⁶⁶, Ruth Walker²⁶⁷, Sara Bandres-Ciga²⁴², Sohini Chowdhury²³⁸, Sonya Dumanis²⁶⁸, Steven Lubbe²⁶⁴, Tao Xie²⁶⁹, Tatiana Foroud²⁷⁰, Thomas Beach²⁷¹, Todd Sherer²³⁸, Yeajin Song²⁴², Dana Lewis²⁷², Shreya Menon²⁷³, Melissa Nirenberg²⁷⁴, Spencer Grant²⁴², Shannon Ballard²⁴², Chad Shaw²⁵³, Sidra Aslam²⁷⁵, Geidy Serrano²⁴⁷, Devin Sharp²⁷⁶, Kensuke Daida²⁴⁸, Rachel Saunders-Pullman²⁷⁴, Michiko Kimura Bruno²⁷⁷, Haydeh Payami²⁷⁸, Ryan Pflingst²³⁸, James B. Leverenz²⁵¹, Elizabeth Disbrow²⁷⁹, Debi Brooks²³⁸, Randy Schekman²⁸⁰, Un Kang²⁸¹, Zbigniew K. Wszolek²⁸², Cyrus Zabetian²⁸³, Zach Chaney²³⁸, Christine Swanson-Fischer²⁴², Conor Hennessey²³⁸, Cassandra Barrett²³⁸, Beate Ritz²⁸⁴, Bradley Boeve²⁸⁵, Ashley Rawls²⁸⁶, Duan Nguyen²⁸⁷, Toan Nguyen²⁸⁷ & Masharip Atadzhonov²⁸⁸

⁸¹Centre Hospitalo-Universitaire Dr Benbadis Constantine, Constantine, Algeria. ⁸²Sanatorio de la Trinidad Mitre- INEBA, Buenos Aires, Argentina. ⁸³Hospital JM Ramos Mejia, Buenos Aires, Argentina. ⁸⁴Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno, Buenos Aires, Argentina. ⁸⁵Somnus Neurology Clinic, Yerevan, Armenia. ⁸⁶Neuroscience Research Australia, Sydney, New South Wales, Australia. ⁸⁷Garvan Institute of Medical Research and Concord Repatriation General Hospital, Darlinghurst, New South Wales, Australia. ⁸⁸Concord Hospital, Concord, New South Wales, Australia. ⁸⁹QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. ⁹⁰QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. ⁹¹Concord Repatriation General Hospital, Sydney, Australia. ⁹²Istanbul Klinik, Baku, Azerbaijan. ⁹³University of Antwerp, Antwerp, Belgium. ⁹⁴Universidade Federal do Rio Grande do Sul / Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. ⁹⁵Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil. ⁹⁶Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. ⁹⁷University of São Paulo, São Paulo, Brazil. ⁹⁸Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. ⁹⁹Institut universitaire de gériatrie de Montréal, Montreal, Quebec, Canada. ¹⁰⁰McGill University, Montreal, Quebec, Canada. ¹⁰¹Aligning Science Across Parkinson's, Vancouver, British Columbia, Canada. ¹⁰²Fundación Diagnóstico, Santiago, Chile. ¹⁰³Facultad de Medicina Universidad de Chile, Santiago, Chile. ¹⁰⁴Universidad de Santiago de Chile, Santiago, Chile. ¹⁰⁵Universidad de Chile, Facultad de Medicina, Santiago, Chile. ¹⁰⁶University of Concepción, Concepción, Chile. ¹⁰⁷Centro de Imagenología, Hospital Clínico, Universidad de Chile, Santiago, Chile. ¹⁰⁸Central South University, Changsha, China. ¹⁰⁹West China Hospital Sichuan University, Chengdu, China. ¹¹⁰Xiangya Hospital, Changsha, China. ¹¹¹Capital Medical University, Beijing, China. ¹¹²Zhejiang University, Hangzhou, China. ¹¹³Xiangya Hospital, Central South University, Changsha, China. ¹¹⁴Universidad Nacional de Colombia, Bogotá, Colombia. ¹¹⁵Fundación Valle del Lili, Santiago De Cali, Colombia. ¹¹⁶University of Antioquia, Medellín, Colombia. ¹¹⁷University of Costa Rica, San Jose, Costa Rica. ¹¹⁸Aarhus University, Aarhus, Denmark. ¹¹⁹The American University in Cairo, Cairo, Egypt. ¹²⁰Beni-Suef University, Beni Suef, Egypt. ¹²¹Addis Ababa University, Addis Ababa, Ethiopia. ¹²²Salpêtrière Hospital (AP-HP), Sorbonne Université, Paris, France. ¹²³Tbilisi State Medical University, Tbilisi, Georgia. ¹²⁴S. Khechinashvili University Hospital, Tbilisi, Georgia. ¹²⁵University of Lübeck, Lübeck, Germany. ¹²⁶Deutsches Zentrum für Neurodegenerative, Göttingen, Germany. ¹²⁷University Medical Center Göttingen, Göttingen, Germany. ¹²⁸Department of Neurology, University Hospital, LMU, Munich, Germany.

¹²⁹University of Lübeck and University Medical Center, Lübeck, Germany. ¹³⁰University of Mainz, Mainz, Germany. ¹³¹The German Center for Neurodegenerative, Göttingen, Germany. ¹³²Charité - Universitätsmedizin Berlin, Berlin, Germany. ¹³³University of Tübingen, Tübingen, Germany. ¹³⁴University Medical Center Schleswig-Holstein, Lübeck, Germany. ¹³⁵Technical University of Munich, Munich, Germany. ¹³⁶University of Ghana Medical School, Accra, Ghana. ¹³⁷University of Thessaly, Volos, Greece. ¹³⁸Aristotle University of Thessaloniki, Thessaloniki, Greece. ¹³⁹Ionian University, Corfu, Greece. ¹⁴⁰Diagnostic and Therapeutic Centre HYGEIA, Marousi, Greece. ¹⁴¹Hospital San Felipe, Tegucigalpa, Honduras. ¹⁴²Queen Elizabeth Hospital, Kowloon, Hong Kong. ¹⁴³The Hong Kong University of Science and Technology, Hong Kong. ¹⁴⁴Aster Medcity, Kochi, India. ¹⁴⁵Sree Chitra Tirunal Institute for Medical Sciences, Thiruvananthapuram, India. ¹⁴⁶National Institute of Mental Health & Neurosciences, Bengaluru, India. ¹⁴⁷Manipal Hospital, Delhi, India. ¹⁴⁸All India Institute of Medical Sciences, Delhi, India. ¹⁴⁹Nizam's Institute Of Medical Sciences, Hyderabad, India. ¹⁵⁰Shahid Beheshti University of Medical Science, Tehran, Iran. ¹⁵¹Tel Aviv Sourasky Medical Center, Tel Aviv-Yafo, Israel. ¹⁵²University of Perugia, Perugia, Italy. ¹⁵³University of Pavia, Pavia, Italy. ¹⁵⁴University of Rome Tor Vergata, Rome, Italy. ¹⁵⁵IRCCS Mondino Foundation, Pavia, Italy. ¹⁵⁶University of Naples Federico II, Naples, Italy. ¹⁵⁷Jikei University School of Medicine, Tokyo, Japan. ¹⁵⁸Institute of Neurology and Neurorehabilitation, Almaty, Kazakhstan. ¹⁵⁹West Kazakhstan Marat Ospanov State Medical Univ, Aktobe, Kazakhstan. ¹⁶⁰Medline medical center, Astana, Kazakhstan. ¹⁶¹National Center for Neurosurgery, Astana, Kazakhstan. ¹⁶²Astana Medical University, Astana, Kazakhstan. ¹⁶³City multi-field hospital No. 1, Astana, Kazakhstan. ¹⁶⁴International University of Post-graduate Education, Almaty, Kazakhstan. ¹⁶⁵South Kazakhstan Medical Academy, Shymkent, Kazakhstan. ¹⁶⁶Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan. ¹⁶⁷University of Malaya, Kuala Lumpur, Malaysia. ¹⁶⁸Universiti Kebangsaan Malaysia, Selangor, Malaysia. ¹⁶⁹UKM Medical Molecular Biology Institute, Kuala Lumpur, Malaysia. ¹⁷⁰Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia. ¹⁷¹International Islamic University, Kuala Lumpur, Malaysia. ¹⁷²Tecnologico de Monterrey, Monterrey, Mexico. ¹⁷³Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico. ¹⁷⁴Universidad Nacional Autónoma de México, Santiago de, Mexico. ¹⁷⁵Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico. ¹⁷⁶Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia. ¹⁷⁷Tribhuvan University, Kirtipur, Nepal. ¹⁷⁸Vanderbilt University Medical Center, Amsterdam, Netherlands. ¹⁷⁹Brain Research and Innovation Center, Amsterdam, Netherlands. ¹⁸⁰University of Otago, Dunedin, New Zealand. ¹⁸¹University of Lagos, Lagos, Nigeria. ¹⁸²College of Medicine of the University of Lagos, Lagos, Nigeria. ¹⁸³University of Calabar Teaching Hospital, Calabar, Nigeria. ¹⁸⁴University of Ilorin, Ilorin, Nigeria. ¹⁸⁵Oslo University Hospital, Oslo, Norway. ¹⁸⁶Stavanger University Hospital, Stavanger, Norway. ¹⁸⁷University of Science and Technology Bannu, Bannu, Pakistan. ¹⁸⁸Universidad Científica del Sur, Lima, Peru. ¹⁸⁹Metropolitan Medical Center, Manila, Philippines. ¹⁹⁰University of Puerto Rico, San Juan, Puerto Rico. ¹⁹¹Research Center of Neurology, Moscow, Russia. ¹⁹²Ufa Federal Research Center, Ufa, Russia. ¹⁹³Ufa Scientific Center, Ufa, Russia. ¹⁹⁴Russian Academy of Sciences / Bashkir State Medica, Ufa, Russia. ¹⁹⁵King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. ¹⁹⁶King Abdullah International Medical Research, Jeddah, Saudi Arabia. ¹⁹⁷National Neuroscience Institute, Singapore, Singapore. ¹⁹⁸Nanyang Technological University, Singapore, Singapore. ¹⁹⁹Ljubljana University Medical Centre, Ljubljana, Slovenia. ²⁰⁰University of KwaZulu-Natal, Durban, South Africa. ²⁰¹University of the Western Cape, Bellville, South Africa. ²⁰²Stellenbosch University, Cape Town, South Africa. ²⁰³Seoul National University Hospital, Seoul, South Korea. ²⁰⁴Yongin Severance Hospital, Seoul, South Korea. ²⁰⁵Seoul National University, Seoul, South Korea. ²⁰⁶Hospital Universitario Burgos, Burgos, Spain. ²⁰⁷University Hospital Mutua Terrassa, Barcelona, Spain. ²⁰⁸Institut de Recerca Sant Joan de Deu, Barcelona, Spain. ²⁰⁹Research Institute Germans Trias i Pujol, Barcelona, Spain. ²¹⁰Instituto de Biomedicina de Sevilla, Seville, Spain. ²¹¹Hospital Clínic de Barcelona, Barcelona, Spain. ²¹²Faculty of medicine university of Khartoum, Khartoum, Sudan. ²¹³Lund University, Lund, Sweden. ²¹⁴Karolinska Institute, Stockholm, Sweden. ²¹⁵Inselspital Bern, University of Bern, Bern, Switzerland. ²¹⁶University Hospital Bern, Bern, Switzerland. ²¹⁷National Taiwan University Hospital, Taipei City, Taiwan. ²¹⁸Chang Gung Memorial Hospital, Taoyuan City, Taiwan. ²¹⁹National Taiwan University, Taipei City, Taiwan. ²²⁰Avicenna Tajik State Medical University, Dushanbe, Tajikistan. ²²¹Mongi Ben Hmida National Institute of Neurology, Tunis, Tunisia. ²²²Koç University, Istanbul, Turkey. ²²³Şişli Etfal Training and Research Hospital, Istanbul, Turkey. ²²⁴Queen Mary University of London, London, United Kingdom. ²²⁵University College London, London, United Kingdom. ²²⁶University of Plymouth, Plymouth, United Kingdom. ²²⁷University of Glasgow, Glasgow, United Kingdom. ²²⁸Cardiff University, Cardiff, United Kingdom. ²²⁹University of Bristol, Bristol, United Kingdom. ²³⁰St George's, University of London, London, United Kingdom. ²³¹University of Cambridge, Cambridge, United Kingdom. ²³²University of Oxford, Oxford, United Kingdom. ²³³Northumbria Healthcare at NHS Foundation Trust, Newcastle upon Tyne, United Kingdom. ²³⁴Imperial College London, London, United Kingdom. ²³⁵Newcastle University, Newcastle upon Tyne, United Kingdom. ²³⁶YLD, London, United Kingdom. ²³⁷University of Cincinnati, Cincinnati, Ohio, USA. ²³⁸The Michael J. Fox Foundation for Parkinson's, New York, New York, USA. ²³⁹Augusta University / University of Georgia Medical, Augusta, Georgia, USA. ²⁴⁰Mid-Atlantic Permanente Medical Group, Bethesda, Maryland, USA. ²⁴¹Washington University, St. Louis, Missouri, USA. ²⁴²National Institutes of Health, Bethesda, Maryland, USA. ²⁴³Indiana University, Bloomington, Indiana, USA. ²⁴⁴Rush University, Chicago, Illinois, USA. ²⁴⁵Kaiser Permanente, Oakland, California, USA. ²⁴⁶Coalition for Aligning Science, Washington, Washington, USA. ²⁴⁷Banner Sun Health Research Institute, Sun City, Arizona, USA. ²⁴⁸National Institute on Aging, Bethesda, Maryland, USA. ²⁴⁹Data Tecnica International, Washington, Washington, USA. ²⁵⁰Michigan State University, East Lansing, Michigan, USA. ²⁵¹Cleveland Clinic, Cleveland, Ohio, USA. ²⁵²Northwestern University, Evanston, Illinois, USA. ²⁵³Baylor College of Medicine, Houston, Texas, USA. ²⁵⁴Baylor College of Medicine / Texas Children's, Houston, Texas, USA. ²⁵⁵Parkinson's Foundation, Princeton, New Jersey, USA. ²⁵⁶University of Miami Miller School of Medicine, Miami, Florida, USA. ²⁵⁷Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. ²⁵⁸North Shore University Health System, Chicago, Illinois, USA. ²⁵⁹Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA. ²⁶⁰University of Pittsburgh, Pittsburgh, Pennsylvania, USA. ²⁶¹Washington University, Saint Louis, Missouri, USA. ²⁶²University of Alabama at Birmingham, Birmingham, Alabama, USA. ²⁶³University of Maryland, Baltimore, Maryland, USA. ²⁶⁴Northwestern University, Chicago, Illinois, USA. ²⁶⁵University of Michigan, Ann Arbor, Michigan, USA. ²⁶⁶Columbia University, New York, New York, USA. ²⁶⁷James J. Peters Veterans Affairs Medical Center, New York, New York, USA. ²⁶⁸Aligning Science Across Parkinson's, Washington, Washington, USA. ²⁶⁹University of Chicago, Chicago, Illinois, USA. ²⁷⁰Indiana University School of Medicine, Indianapolis, Indiana, USA. ²⁷¹Sun Health Research Institution, City, Arizona, USA. ²⁷²Aligning Science Across Parkinson's, Baltimore, Maryland, USA. ²⁷³Gladstone Institutes, San Francisco, California, USA. ²⁷⁴Icahn School of Medicine at Mount Sinai, New York, New York, USA. ²⁷⁵Banner Health, Phoenix, Arizona, USA. ²⁷⁶Aligning Science Across Parkinson's, Vancouver, British Columbia, USA. ²⁷⁷The Queen's Medical Center, Honolulu, Hawaii, USA. ²⁷⁸The University of Alabama at Birmingham Heersink, Birmingham School of Medicine, Alabama, USA. ²⁷⁹LSU Health Shreveport, Shreveport, Louisiana, USA. ²⁸⁰University of California, Berkeley, Berkeley, California, USA. ²⁸¹NYU Grossman School of Medicine, New York, New York, USA. ²⁸²Mayo Clinic College of Medicine, Rochester, Minnesota, USA. ²⁸³VA Puget Sound Health Care System, Seattle, Washington, USA. ²⁸⁴University of California, Los Angeles, Los Angeles, California, USA. ²⁸⁵Mayo Clinic, Rochester, Minnesota, USA. ²⁸⁶University of Florida College of Medicine, Gainesville, Florida, USA. ²⁸⁷Hue University, Huế, Vietnam. ²⁸⁸University of Zambia, Lusaka, Zambia.

the Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease (COURAGE-PD) consortium

Cloé Domenighetti¹², Pierre-Emmanuel Sugier¹², Ashwin Ashok Kumar Sreelatha³, Claudia Schulte^{6,7}, Berta Portugal¹⁴, Patrick May^{1,289}, Dheeraj Reddy Bobbili¹, Milena Radivojkov-Blagojevic¹³, Peter Lichtner¹³, Andrew B. Singleton^{4,15}, Dena G. Hernandez¹⁵, Connor Edsall¹⁵, George D. Mellick¹⁷, Alexander Zimprich¹⁸, Walter Pirker¹⁹, Ekaterina Rogaeva²¹,

Anthony Lang^{21,22,23,24}, Sulev Koks^{25,26}, Pille Taba^{27,28}, Suzanne Lesage²⁹, Alexis Brice²⁹, Jean-Christophe Corvol^{29,30}, Marie-Christine Chartier-Harlin³¹, Eugenie Mutez³¹, Kathrin Brockmann^{6,7}, Angela B. Deutschländer^{32,33,34}, Georges M. Hadjigeorgiou^{35,36}, Efthimos Dardiotis³⁶, Leonidas Stefanis^{37,38}, Athina Maria Simitsi³⁸, Enza Maria Valente^{39,40}, Simona Petrucci^{41,42}, Letizia Straniero⁴³, Anna Zecchinelli⁴⁴, Gianni Pezzoli^{44,45}, Laura Brighina^{46,47}, Carlo Ferrarese^{46,47}, Grazia Annesi⁴⁸, Andrea Quattrone⁴⁹, Monica Gagliardi⁵⁰, Hirotaka Matsuo⁵⁴, Akiyoshi Nakayama⁵⁴, Nobutaka Hattori⁵⁵, Kenya Nishioka⁵⁵, Sun Ju Chung⁵⁶, Yun Joong Kim⁵⁷, Pierre Kolber⁵⁸, Bart P. C. van de Warrenburg⁵⁹, Bastiaan R. Bloem⁵⁹, Mathias Toft⁶⁰, Lasse Pihlstrom⁶⁰, Leonor Correia Guedes^{61,62}, Joaquim J. Ferreira^{61,63}, Soraya Bardien^{64,65}, Jonathan Carr⁶⁶, Eduardo Tolosa^{67,68}, Mario Ezquerra⁶⁹, Pau Pastor^{70,71}, Karin Wirdefeldt^{72,73}, Nancy L. Pedersen⁷³, Caroline Ran⁷⁴, Andrea C. Belin⁷⁴, Andreas Puschmann⁷⁵, Carl E. Clarke⁷⁶, Karen E. Morrison⁷⁷, Manuela Tan²⁰, Dimitri Krainc⁵¹, Lena F. Burbulla^{7,51,52,53}, Matt J. Farrer⁷⁸, Rejko Krüger^{1,2,58}, Thomas Gasser^{6,7}, Manu Sharma^{3,289} ✉ & Alexis Elbaz¹²